Strengthening the commercial forecast for a rare disease asset.

A biotech company was preparing for a major leadership discussion on the commercial outlook for a rare disease asset. The team already had a forecast model, but there was growing concern that some of the assumptions behind it had not been tested rigorously enough. Competitive entry timing was uncertain, pricing and access assumptions across Europe had been simplified, and the expected adoption curve looked more confident than the market reality was likely to support.

DSX was asked to review and strengthen the commercial framework behind the forecast. The work focused on market definition, competitive evolution, regional pricing and access dynamics, adoption assumptions, and scenario analysis around the variables most likely to change the outcome. Rather than rebuilding the model from scratch, the aim was to make the forecast more realistic, more transparent and more useful in the decision it needed to support. This reflects DSX's forecast architecture work around competitive modelling, pricing and access integration, scenario analysis, and support for investment or governance decisions.

The leadership team came away with a clearer view of the opportunity, a stronger understanding of the risks in the original forecast, and a more credible set of scenarios for discussion. The forecast became easier to explain, easier to challenge constructively, and more useful as a basis for decision-making.